Press Releases

- Primary endpoint of placebo-adjusted reduction in awake cough frequency did not reach statistical significance - - Highly statistically significant and clinically meaningful reductions in placebo adjusted awake cough frequency achieved in pre-specified analysis of high cough count patients

LAVAL, Quebec --(BUSINESS WIRE)--May 28, 2020-- BELLUS Health Inc. (Nasdaq: BLU; TSX: BLU) (“BELLUS Health” or the “Company”), a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of chronic cough and other hypersensitization-related disorders, today announced

LAVAL, Quebec --(BUSINESS WIRE)--May 14, 2020-- BELLUS Health Inc. (Nasdaq: BLU; TSX: BLU) (“BELLUS Health” or the “Company”), a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of chronic cough and other hypersensitization-related disorders, today reported

LAVAL, Quebec --(BUSINESS WIRE)--May 13, 2020-- BELLUS Health Inc. (Nasdaq: BLU; TSX: BLU) (" BELLUS Health " or the "Company"), a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of chronic cough and other hypersensitization-related disorders, today

LAVAL, Quebec --(BUSINESS WIRE)--May 6, 2020-- BELLUS Health Inc. (Nasdaq: BLU; TSX: BLU) (“BELLUS Health” or the “Company”), a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of chronic cough and other hypersensitization-related disorders, today announced

Meeting to be held by webcast as a result of public health measures in response to the COVID-19 pandemic LAVAL, Quebec --(BUSINESS WIRE)--May 5, 2020-- BELLUS Health Inc. (Nasdaq: BLU; TSX: BLU) (“BELLUS Health” or the “Company”), a clinical-stage biopharmaceutical company developing novel

- Topline data on track for mid-year 2020 - LAVAL, Quebec --(BUSINESS WIRE)--Apr. 6, 2020-- BELLUS Health Inc. (Nasdaq: BLU; TSX: BLU) (the “Company” or “BELLUS Health”) , a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of chronic cough and other

- BELLUS now owns 100% of BLU-5937 and related P2X3 antagonist intellectual property with no future payments due - - 4.77 million BELLUS Health common shares issued in consideration - LAVAL, Quebec --(BUSINESS WIRE)--Mar. 25, 2020-- BELLUS Health Inc. (Nasdaq: BLU; TSX: BLU) (the “Company” or

- BELLUS to own 100% of BLU-5937 and related P2X3 antagonists intellectual property with no future payments due - - 4.77 million BELLUS Health common shares to be issued in consideration - LAVAL, Quebec --(BUSINESS WIRE)--Mar. 23, 2020-- BELLUS Health Inc. (Nasdaq: BLU; TSX: BLU) (the “Company” or

- On track to report topline data from the RELIEF trial in mid-2020 - LAVAL, Quebec --(BUSINESS WIRE)-- BELLUS Health Inc. (Nasdaq:BLU; TSX:BLU) (the “Company” or “BELLUS Health”), a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of chronic cough and other